102 related articles for article (PubMed ID: 11472206)
61. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
62. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
63. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells.
Kanda N; Watanabe S
Biochem Pharmacol; 2001 Aug; 62(4):495-507. PubMed ID: 11448460
[TBL] [Abstract][Full Text] [Related]
64. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
65. Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.
Singh B; Lesher GY; Pluncket KC; Pagani ED; Bode DC; Bentley RG; Connell MJ; Hamel LT; Silver PJ
J Med Chem; 1992 Dec; 35(26):4858-65. PubMed ID: 1336055
[TBL] [Abstract][Full Text] [Related]
66. 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
Bourguignon JJ; Désaubry L; Raboisson P; Wermuth CG; Lugnier C
J Med Chem; 1997 Jun; 40(12):1768-70. PubMed ID: 9191951
[No Abstract] [Full Text] [Related]
67. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
68. Type IV phosphodiesterase activity specifically regulates cAMP-stimulated casein secretion in the rat mammary gland.
Pooley L
Biochim Biophys Acta; 2002 Jun; 1590(1-3):84-92. PubMed ID: 12063171
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
Zhang HT; Crissman AM; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2000 Aug; 23(2):198-204. PubMed ID: 10882846
[TBL] [Abstract][Full Text] [Related]
70. 3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.
Raichurkar AV; Shah UA; Kulkarni VM
Med Chem; 2011 Nov; 7(6):543-52. PubMed ID: 22313294
[TBL] [Abstract][Full Text] [Related]
71. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
Macdonald D; Perrier H; Liu S; Laliberté F; Rasori R; Robichaud A; Masson P; Huang Z
J Med Chem; 2000 Oct; 43(21):3820-3. PubMed ID: 11052785
[No Abstract] [Full Text] [Related]
72. Solid-phase synthesis of an arylsulfone hydroxamate library.
Salvino JM; Mathew R; Kiesow T; Narensingh R; Mason HJ; Dodd A; Groneberg R; Burns CJ; McGeehan G; Kline J; Orton E; Tang SY; Morrisette M; Labaudininiere R
Bioorg Med Chem Lett; 2000 Aug; 10(15):1637-40. PubMed ID: 10937713
[TBL] [Abstract][Full Text] [Related]
73. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
Cashman JR; Voelker T; Zhang HT; O'Donnell JM
J Med Chem; 2009 Mar; 52(6):1530-9. PubMed ID: 19256502
[TBL] [Abstract][Full Text] [Related]
74. Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
Zheng S; Kaur G; Wang H; Li M; Macnaughtan M; Yang X; Reid S; Prestegard J; Wang B; Ke H
J Med Chem; 2008 Dec; 51(24):7673-88. PubMed ID: 19049349
[TBL] [Abstract][Full Text] [Related]
75. Carbon 14 and stable isotope synthesis of two potent and selective phosphodiesterase type 4 inhibitors.
Latli B; Hrapchak MJ; Tampone TG; Frutos RP; Lee H
J Labelled Comp Radiopharm; 2023 Sep; 66(11):353-361. PubMed ID: 37487707
[TBL] [Abstract][Full Text] [Related]
76. Hydrophenanthrene Construction by Aryl Radical Cyclization. Synthesis of 2,3,4,4a,9,10-Hexahydro-7-methoxy- 4a-methylphenanthren-2-one.
Schultz AG; Wang A
J Org Chem; 1996 Jul; 61(14):4857-4859. PubMed ID: 11667431
[No Abstract] [Full Text] [Related]
77. Synthesis and crystal structure of 2,3,12,13-tetraalkoxy-21, 23-dithiaporphyrins.
Agarwal N; Mishra SP; Kumar A; Hung CH; Ravikanth M
Chem Commun (Camb); 2002 Nov; (22):2642-3. PubMed ID: 12510277
[TBL] [Abstract][Full Text] [Related]
78. Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A.
Hernandez I; Ward E; Pettus TRR; Reich NO
ACS Med Chem Lett; 2024 May; 15(5):590-594. PubMed ID: 38746896
[TBL] [Abstract][Full Text] [Related]
79. Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies.
Jamabo M; Mahlalela M; Edkins AL; Boshoff A
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569903
[TBL] [Abstract][Full Text] [Related]
80. Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening.
de Heuvel E; Kooistra AJ; Edink E; van Klaveren S; Stuijt J; van der Meer T; Sadek P; Mabille D; Caljon G; Maes L; Siderius M; de Esch IJP; Sterk GJ; Leurs R
Front Chem; 2020; 8():608030. PubMed ID: 33553105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
